Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients.
作者信息
Tanaka Masami, Yokoyama Kaho
机构信息
Multiple Sclerosis Center, Utano National Hospital, Kyoto, Japan.
Department of Pharmacy, Utano National Hospital, Kyoto, Japan.
出版信息
Mult Scler J Exp Transl Clin. 2016 Feb 19;2:2055217316632776. doi: 10.1177/2055217316632776. eCollection 2016 Jan-Dec.
Abstract
摘要
相似文献
1
Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients.
Mult Scler J Exp Transl Clin. 2016 Feb 19;2:2055217316632776. doi: 10.1177/2055217316632776. eCollection 2016 Jan-Dec.
2
Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
Neurodegener Dis Manag. 2015 Oct;5(5):399-402. doi: 10.2217/nmt.15.42. Epub 2015 Oct 30.
3
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
Mult Scler. 2018 May;24(6):805-810. doi: 10.1177/1352458517708464. Epub 2017 May 9.
4
Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
Cytometry B Clin Cytom. 2018 Mar;94(2):327-333. doi: 10.1002/cyto.b.21527. Epub 2017 Apr 17.
5
Extended interval dosing of natalizumab in multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25.
6
Efficacy and safety of natalizumab extended interval dosing.
Mult Scler Relat Disord. 2018 Aug;24:113-116. doi: 10.1016/j.msard.2018.06.015. Epub 2018 Jul 5.
7
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
J Clin Pharmacol. 2016 Oct;56(10):1254-62. doi: 10.1002/jcph.707. Epub 2016 Mar 3.
8
Fatal COVID-19 in an MS patient on natalizumab: A case report.
Mult Scler J Exp Transl Clin. 2020 Aug 10;6(3):2055217320942931. doi: 10.1177/2055217320942931. eCollection 2020 Jul-Sep.
9
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
J Neurol Sci. 2015 Nov 15;358(1-2):201-6. doi: 10.1016/j.jns.2015.08.1537. Epub 2015 Aug 29.
10
Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.
Neurol Ther. 2017 Jun;6(1):39-55. doi: 10.1007/s40120-016-0059-z. Epub 2016 Dec 5.
引用本文的文献
1
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.
J Pers Med. 2021 Dec 10;11(12):1347. doi: 10.3390/jpm11121347.
本文引用的文献
1
Body weight-based natalizumab treatment in adult patients with multiple sclerosis.
J Neurol. 2015 Mar;262(3):781-2. doi: 10.1007/s00415-015-7655-1. Epub 2015 Feb 7.
2
Extended interval dosing of natalizumab: a two-center, 7-year experience.
Ther Adv Neurol Disord. 2014 Sep;7(5):227-31. doi: 10.1177/1756285614540224.
3
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
Int Immunol. 2015 Jan;27(1):47-53. doi: 10.1093/intimm/dxu096. Epub 2014 Oct 17.
4
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.
Neurology. 2009 Feb 3;72(5):402-9. doi: 10.1212/01.wnl.0000341766.59028.9d.
Zotero 插件